Fig. 2

Overview of NFE2L2 mutations and Nrf2-activating mutations in the OrigiMed cohort. (A) The NFE2L2 mutations profiles and the clinical characters of 10,194 patients. (B) Distribution of NFE2L2 mutations according to locations of the mutation. (C) Co-occurrence/mutual exclusivity of NFE2L2 and other genes. (D) The prevalence of Nrf2-activating mutations, Nrf2-inactivating mutations and unknown NFE2L2 mutations in each cancer type. Violin plots of TMB (E) and mutation count (F) among four groups: Nrf2-activating mutations, Nrf2-inactivating mutations, unknown NFE2L2 mutations and WT groups. TMB: tumor mutation burden. WT: wide type